Loading organization details...
Loading organization details...
WE PROVIDE HIGHLY EFFECTIVE MENTAL HEALTH AND ADDICTION TREATMENT THAT HELPS PEOPLE REACH FULL POTENTIAL FOR HEALTH AND WELL-BEING.
Source: IRS Form 990 (Tax Year 2024)
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$346.8M
Program Spending
78%
of total expenses go to program services
Total Contributions
$253.6K
Total Expenses
▼$338.9M
Total Assets
$647.8M
Total Liabilities
▼$290.6M
Net Assets
$357.2M
Officer Compensation
→$3M
Other Salaries
$195.1M
Investment Income
$11.3M
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
Total Federal Funding
$128.5K
Awards Found
1
Department of Health and Human Services
$128.5K
TREATING OBSESSIVE-COMPULSIVE DISORDER DURING THE PERINATAL PERIOD - PROJECT SUMMARY/ABSTRACT THE PERINATAL PERIOD (PREGNANCY THROUGH ONE YEAR AFTER GIVING BIRTH) IS A TIME OF SIGNIFICANTLY ELEVATED RISK FOR BOTH THE ONSET AND EXACERBATION OF OBSESSIVE-COMPULSIVE DISORDER (OCD). OCD IS DEBILITATING AND COSTLY IN THE GENERAL POPULATION, BUT FOR PERINATAL WOMEN UNTREATED OCD CONFERS A HOST OF ADDITIONAL RISKS RANGING FROM SERIOUS DELIVERY COMPLICATIONS TO DELETERIOUS HEALTH OUTCOMES FOR BOTH THE PARENT AND INFANT. ALTHOUGH EFFECTIVE TREATMENTS FOR OCD EXIST, PARTICULARLY EXPOSURE AND RESPONSE PREVENTION (ERP) AND SEROTONIN REUPTAKE INHIBITORS (SRIS), THESE TREATMENTS HAVE NOT BEEN SYSTEMATICALLY STUDIED IN PERINATAL WOMEN IN PART BECAUSE PREGNANT INDIVIDUALS HAVE BEEN EXCLUDED FROM CLINICAL TRIALS DUE TO SAFETY CONCERNS. HOWEVER, PERINATAL WOMEN ARE PHYSIOLOGICALLY AND PSYCHOLOGICALLY DISTINCT FROM THE NON-PERINATAL SAMPLES ON WHOM ERP AND SRIS WERE EMPIRICALLY TESTED, AND THERE ARE MANY REASONS TO EXPECT THAT THE UNIQUE BIOLOGICAL AND PSYCHOSOCIAL CONTEXT OF PERINATAL WOMEN MIGHT UNDERMINE THE EFFICACY, TOLERABILITY, AND SAFETY OF FIRST-LINE OCD TREATMENTS. DESPITE THE DEARTH OF DATA AND THE NUMEROUS WAYS THAT PERINATAL-SPECIFIC CONSIDERATIONS ALTER THE TREATMENT CONTEXT, BOTH PREGNANT AND POSTPARTUM WOMEN SUFFERING FROM OCD ROUTINELY PRESENT TO REAL-WORLD CLINICAL SETTINGS SEEKING TREATMENT. TO RESPOND TO THIS MATERNAL AND FILIAL HEALTH CRISIS, RESEARCH IS URGENTLY NEEDED TO DETERMINE IF FIRST- LINE OCD TREATMENTS ARE EFFECTIVE, SAFE, AND TOLERABLE FOR PERINATAL WOMEN, AND HOW STANDARD CARE NEEDS TO BE TAILORED TO FIT THE PERINATAL CONTEXT. THIS PROPOSAL WILL LEVERAGE EXISTING PATIENT DATA COLLECTED AS PART OF STANDARD CARE AT A LARGE NATURALISTIC BEHAVIORAL HEALTHCARE SYSTEM TO ADDRESS THIS CRITICAL, YET DIFFICULT TO STUDY, CLINICAL ISSUE AND INFORM LARGER-SCALE RANDOMIZED-CONTROLLED TRIALS (RCTS) AIMED AT IMPROVING OUTCOMES FOR BIRTHING PARENTS AND THEIR FAMILIES. USING THE LARGEST PERINATAL OCD SAMPLE TO DATE (N = 94; 43 PREGNANT, 51 POSTPARTUM) AND AN EQUAL NUMBER OF PROPENSITY-SCORE-MATCHED NON-PERINATAL CONTROLS (TOTAL N = 188), THIS STUDY WILL IMPLEMENT A CASE-CONTROL DESIGN, RETROSPECTIVE CHART REVIEW, AND STATISTICAL MODELING TO EVALUATE THE FOLLOWING AIMS: 1) DETERMINE WHICH INTERVENTIONS ARE ADMINISTERED TO PERINATAL PATIENTS WITH OCD IN A NATURALISTIC SETTING; 2) EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF FIRST-LINE OCD TREATMENTS IN THE PERINATAL PERIOD; AND, 3) TO INFORM PERSONALIZING EFFORTS, EXPLORE HOW STANDARD TREATMENTS ARE ADAPTED FOR USE WITH PERINATAL PATIENTS AND WHETHER THESE MODIFICATIONS IMPROVE OUTCOMES. THIS PROPOSAL IS IN LINE WITH THE STRATEGIC RESEARCH PRIORITIES SET FORTH BY THE NIMH PERTAINING TO INVESTIGATING PERSONALIZED INTERVENTION STRATEGIES (OBJECTIVE 3.2.A), ESTABLISHING THE SAFETY AND EFFICACY OF INTERVENTIONS FOR WOMEN AT VARIOUS PHASES OF THE REPRODUCTIVE CYCLE (INTEREST AREA 3), AND THE NEED FOR ADDITIONAL RESEARCH ON WOMEN’S MENTAL HEALTH DURING THE PERINATAL PERIOD (NOT-MH-21-270). THIS STUDY WILL PROVIDE PRELIMINARY DATA ATTESTING TO THE SAFETY, TOLERABILITY, AND EFFICACY OF STANDARD AND MODIFIED OCD TREATMENTS IN THE PERINATAL PERIOD, THEREBY JUSTIFYING THE INCLUSION OF PREGNANT PARTICIPANTS IN A LARGER-SCALE RCT TO BE PROPOSED IN A SUBSEQUENT R61/R33 APPLICATION AND INFORMING THE NATURE OF THE TREATMENTS TO BE EVALUATED.
Source: Federal Audit Clearinghouse (fac.gov)
Total Audits
1
Clean Audits
1
Material Weakness
No
Noncompliance Issues
No
| Year | Status | Financial Report | Federal Expenditure | Low Risk | Accepted |
|---|---|---|---|---|---|
| 2021 | Clean | Unmodified (Clean) | $3.5M | No | 2022-04-28 |
Financial Report
Unmodified (Clean)
Federal Expenditure
$3.5M
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $346.8M | $253.6K | $338.9M | $647.8M | $357.2M |
| 2023 | $354.4M | $0 | $345.5M | $549.6M | $337.3M |
| 2022 | $340.4M | $0 | $316.2M | $507.7M | $315M |
| 2021 | $335.7M | $105.5K |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File | |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Cynthia Meyer | President And CEO | 0.1 | $0 | $1.1M | $44.4K | $1.1M |
| Chris Jagoditz | CFO | 0.1 | $0 | $451.7K | $53.5K | $505.1K |
| Colleen Kelly | Cco | 40 | $278.8K | $0 | $80.2K | $358.9K |
| Barb Gormacki | Board Chair | 3 | $0 | $0 | $0 | $0 |
| Bob Olson | Board Vice-chair | 3 | $0 | $0 | $0 | $0 |
| Michael Sevi | Board Secretary | 3 | $0 | $0 | $0 | $0 |
| William T Mulligan | Board Treasurer | 3 | $0 | $0 | $0 | $0 |
Cynthia Meyer
President And CEO
$1.1M
Hrs/Wk
0.1
Compensation
$0
Related Orgs
$1.1M
Other
$44.4K
Chris Jagoditz
CFO
$505.1K
Hrs/Wk
0.1
Compensation
$0
Related Orgs
$451.7K
Other
$53.5K
Colleen Kelly
Cco
$358.9K
Hrs/Wk
40
Compensation
$278.8K
Related Orgs
$0
Other
$80.2K
Barb Gormacki
Board Chair
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Bob Olson
Board Vice-chair
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Michael Sevi
Board Secretary
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
William T Mulligan
Board Treasurer
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Christopher Takala | Medical Director | 40 | $637.6K | $0 | $53.4K | $691K |
| Syed Hussaini | Medical Director | 40 | $623.2K | $0 | $50.6K | $673.7K |
| Jerry Halverson Md | Cmo | 40 | $556.7K | $0 | $90.8K | $647.6K |
| Cuong Tieu | Medical Director | 40 | $567.7K | $0 | $49K | $616.7K |
| Hemalatha Rajanna | Medical Director | 40 | $604.9K | $0 | $10.8K | $615.7K |
| Keyur Parikh |
Christopher Takala
Medical Director
$691K
Hrs/Wk
40
Compensation
$637.6K
Related Orgs
$0
Other
$53.4K
Syed Hussaini
Medical Director
$673.7K
Hrs/Wk
40
Compensation
$623.2K
Related Orgs
$0
Other
$50.6K
Jerry Halverson Md
Cmo
$647.6K
Hrs/Wk
40
Compensation
$556.7K
Related Orgs
$0
Other
$90.8K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Cal Schmidt | Board Member | 1 | $0 | $0 | $0 | $0 |
| Christy Kaufman | Board Member | 1 | $0 | $0 | $0 | $0 |
| Erik Cardenas | Board Member | 1 | $0 | $0 | $0 | $0 |
| Gina Markson Magnus | Board Member | 1 | $0 | $0 | $0 | $0 |
| Kamilah Williams-Kemp | Board Member | 1 | $0 | $0 | $0 | $0 |
| Karl Gouverneur | Board Member |
Cal Schmidt
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Christy Kaufman
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Erik Cardenas
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Individuals who previously served as officers or key employees.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Bradley Reimann | Former Cco - Termed 07/2023 | — | $464.9K | $0 | $0 | $464.9K |
| John Boyd Former | CEO - Termed 05/2023 | — | $445.5K | $0 | $0 | $445.5K |
| Terri Cohn | Former Cno - Termed 10/2023 | — | $195.1K | $0 | $0 | $195.1K |
Bradley Reimann
Former Cco - Termed 07/2023
$464.9K
Hrs/Wk
—
Compensation
$464.9K
Related Orgs
$0
Other
$0
John Boyd Former
CEO - Termed 05/2023
$445.5K
Hrs/Wk
—
Compensation
$445.5K
Related Orgs
$0
Other
$0
Terri Cohn
Former Cno - Termed 10/2023
$195.1K
Hrs/Wk
—
Compensation
$195.1K
Related Orgs
$0
Other
$0
| $284.5M |
| $501.3M |
| $300.7M |
| 2020 | $289.9M | $108.9K | $253.9M | $448.8M | $234M |
| 2019 | $235.9M | $79.6K | $214.4M | $307.9M | $194.3M |
| 2018 | $205M | $575.2K | $186.3M | $265.5M | $164.5M |
| 2017 | $180.6M | $334.8K | $168.2M | $240.2M | $143.7M |
| 2016 | $160.2M | $270.2K | $147.7M | $223M | $128.9M |
| 2015 | $123.8M | $322.2K | $116.9M | $207.1M | $113.6M |
| 2014 | $100.2M | $155.3K | $89M | $150.9M | $107.7M |
| 2013 | $93.8M | $779.7K | $77.6M | $137.6M | $94.9M |
| 2012 | $80.8M | $122.6K | $70M | $119.9M | $77.6M |
| 2011 | $72.9M | $108.5K | $61.2M | $109.2M | $65.7M |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| Medical Director |
| 40 |
| $551.2K |
| $0 |
| $54.7K |
| $605.9K |
| Brian Kay | Cso | 40 | $342.5K | $0 | $64.5K | $407K |
| Ashley Muchnick | COO | 40 | $352K | $0 | $17.8K | $369.7K |
| Stephanie Eken Assistant | Cmo - Termed 02/2024 | 40 | $271.3K | $0 | $44.7K | $316K |
| Alessandro Vagnini | Cno | 40 | $250.1K | $0 | $24.1K | $274.2K |
Cuong Tieu
Medical Director
$616.7K
Hrs/Wk
40
Compensation
$567.7K
Related Orgs
$0
Other
$49K
Hemalatha Rajanna
Medical Director
$615.7K
Hrs/Wk
40
Compensation
$604.9K
Related Orgs
$0
Other
$10.8K
Keyur Parikh
Medical Director
$605.9K
Hrs/Wk
40
Compensation
$551.2K
Related Orgs
$0
Other
$54.7K
Brian Kay
Cso
$407K
Hrs/Wk
40
Compensation
$342.5K
Related Orgs
$0
Other
$64.5K
Ashley Muchnick
COO
$369.7K
Hrs/Wk
40
Compensation
$352K
Related Orgs
$0
Other
$17.8K
Stephanie Eken Assistant
Cmo - Termed 02/2024
$316K
Hrs/Wk
40
Compensation
$271.3K
Related Orgs
$0
Other
$44.7K
Alessandro Vagnini
Cno
$274.2K
Hrs/Wk
40
Compensation
$250.1K
Related Orgs
$0
Other
$24.1K
| 1 |
| $0 |
| $0 |
| $0 |
| $0 |
| Kenneth Bastin Md | Board Member | 1 | $0 | $0 | $0 | $0 |
| Khazi Muqeet Md | Assoc. Cmo And Board Member | 40 | $621.9K | $0 | $15.2K | $637K |
| Laurie Lafontaine | Board Member | 1 | $0 | $0 | $0 | $0 |
| Marty Borell | Board Member | 1 | $0 | $0 | $0 | $0 |
| Maureen Stapleton | Board Member | 1 | $0 | $0 | $0 | $0 |
Gina Markson Magnus
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Kamilah Williams-Kemp
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Karl Gouverneur
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Kenneth Bastin Md
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Khazi Muqeet Md
Assoc. Cmo And Board Member
$637K
Hrs/Wk
40
Compensation
$621.9K
Related Orgs
$0
Other
$15.2K
Laurie Lafontaine
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Marty Borell
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Maureen Stapleton
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0